# Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

> **NCT00861965** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mirror Biologics, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AlloStim-8
- **BIOLOGICAL:** AlloStim-8
- **BIOLOGICAL:** AlloStim-8
- **BIOLOGICAL:** AlloStim-8

## Key facts

- **NCT ID:** NCT00861965
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** withdrawn due to poor recruitment
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861965, "Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00861965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*